Bruker AXS and Bruker Optics Introduce D8 SCREENLAB(TM), a Combined XRD and Raman High-Throughput Screening System for Advanced Materials Research.ORLANDO, Fla. -- At Pittcon 2006, Bruker AXS Inc. today launches its new D8 SCREENLAB(TM), a screening system which combines the analytical power of two-dimensional X-ray diffraction (XRD XRD X-Ray Diffraction XRD Crossroad XRD X-Ray Diode 2) and Raman spectroscopy. The D8 SCREENLAB integrates the Bruker AXS D8 DISCOVER XRD2 system for combinatorial materials screening with the Bruker Optics Raman probe into one combined advanced materials discovery solution. In the D8 SCREENLAB, the X-ray source, optics and unique 2D X-ray detector, as well as the laser source, the Raman probe and an auto-zoomed video microscope are all integrated into one single platform. As a result, the X-ray diffraction pattern, the Raman spectrum as well as the optical image from the same sample can be obtained in one sample run from a materials library. The powerful PolySNAP(TM) pattern matching software of the D8 SCREENLAB allows the processing of XRD2 and Raman data, and correlates the analysis results. Professor Chris Frampton, Chief Scientific Officer for Pharmorphix Ltd., Cambridge, UK, states: "Combinatorial discovery and optimization methods require rapid screening to evaluate variations of composition, structure and property within advanced materials libraries. While X-ray diffraction provides information on the atomic arrangement in the sample, Raman spectroscopy measures the characteristic vibration frequencies determined by the chemical bonds. Both X-ray diffraction and Raman spectroscopy are non-destructive methods that require little or no sample preparation, thus allowing samples to be analyzed simply and quickly in their natural form. A combined instrument with both XRD and Raman capabilities is very beneficial to high-throughput combinatorial screening in advanced materials and catalyst discovery. In the pharmaceutical industry, screening based on spectroscopic spec·tro·scope n. An instrument for producing and observing spectra. spec  tro·scop and diffraction techniques can be important for drug formulations since the polymorphism of active ingredients has to be controlled to achieve reliable product quality which will satisfy regulatory authorities. The addition of Raman spectroscopy provides even better discrimination in cases where the X-ray data are ambiguous." Dr. Bob He, Director of R&D for Bruker AXS, adds: "Scientists and engineers from both Bruker AXS and Bruker Optics worked jointly to integrate the best technologies from the two companies into this innovative systems solution. With the combination of two analytical methods, the novel D8 SCREENLAB allows our customers to explore new opportunities in advanced materials research." Pittcon 2006, the 57th Pittsburgh Conference and Exposition on Analytical Chemistry and Applied Spectroscopy, is being held March 13-16 in Orlando, Florida in the Orange County Convention Center The Orange County Convention Center (OCCC) is the primary public convention center in Central Florida. The large complex is located on International Drive, a major tourist area in Orlando, Florida. . The D8 SCREENLAB will be exhibited at the Bruker AXS booth, #3155. ABOUT BRUKER BIOSCIENCES (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ) Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. , headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC NBC in full National Broadcasting Co. Major U.S. commercial broadcasting company. It was formed in 1926 by RCA Corp., General Electric Co. (GE), and Westinghouse and was the first U.S. company to operate a broadcast network. ) detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com ABOUT BRUKER OPTICS Bruker Optics Inc is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , which manufactures and distributes analytical and process analysis instruments based on infrared, near-infrared, Raman and TD-NMR spectroscopy. These products are utilized in industry, government and academia for a wide range of applications, such as chemical, polymer, forensic, and pharmaceuticals. The company is based in Billerica, Massachusetts and has manufacturing facilities in Ettlingen, Germany and The Woodlands, Texas. For more information, please visit http://www.brukeroptics.com CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion